Vaxcyte, Inc. — Investor Relations & Filings

Vaxcyte, Inc. is a clinical-stage vaccine innovation company dedicated to developing vaccines to prevent or treat bacterial infectious diseases. The company's primary focus is its pneumococcal conjugate vaccine (PCV) franchise, featuring lead candidates VAX-24 and VAX-31, which are designed to prevent invasive pneumococcal disease (IPD) in adults and children. Vaxcyte utilizes a proprietary cell-free protein synthesis platform, along with advanced chemistry and synthetic techniques, to engineer broad-spectrum, high-fidelity vaccines. This approach aims to overcome the limitations of conventional vaccine methods by enabling the rapid design and production of candidates that can address complex bacterial defense mechanisms while maintaining robust immunogenicity. The company's pipeline also includes early-stage development programs for vaccines targeting Group A Strep and Shigella.